OTSUKA AMERICA PHARMACEUTICAL, INC. for OTSUKA AMERICA PHARMACEUTICAL, INC.
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Science/Technology SCI
Education on Otsuka as a company Improving the U.S. mental health care delivery system Lack of innovative therapies for Renal patients who have CKD stage 1 and 2
| Lobbyist | Covered position, as disclosed |
|---|---|
| HEIDE BAJNRAUH New | — |
| JOHN BARDI New | — |
| JOHN JONAS New | — |
| MOLLY RYAN New | — |
| KAREN THIEL New | — |
| RICHARD THOMPSON New | — |
Alcohol and Drug Abuse ALC
Education on Otsuka as a company Improving the U.S. mental health care delivery system Lack of innovative therapies for Renal patients who have CKD stage 1 and 2
| Lobbyist | Covered position, as disclosed |
|---|---|
| HEIDE BAJNRAUH New | — |
| JOHN BARDI New | — |
| JOHN JONAS New | — |
| MOLLY RYAN New | — |
| KAREN THIEL New | — |
| RICHARD THOMPSON New | — |
Health Issues HCR
Education on Otsuka as a company Improving the U.S. mental health care delivery system Lack of innovative therapies for Renal patients who have CKD stage 1 and 2
| Lobbyist | Covered position, as disclosed |
|---|---|
| HEIDE BAJNRAUH New | — |
| JOHN BARDI New | — |
| JOHN JONAS New | — |
| MOLLY RYAN New | — |
| KAREN THIEL New | — |
| RICHARD THOMPSON New | — |
Medicare/Medicaid MMM
Education on Otsuka as a company Improving the U.S. mental health care delivery system Lack of innovative therapies for Renal patients who have CKD stage 1 and 2
| Lobbyist | Covered position, as disclosed |
|---|---|
| HEIDE BAJNRAUH New | — |
| JOHN BARDI New | — |
| JOHN JONAS New | — |
| MOLLY RYAN New | — |
| KAREN THIEL New | — |
| RICHARD THOMPSON New | — |
Consumer Issues/Safety/Products CSP
Education on Otsuka as a company Improving the U.S. mental health care delivery system Lack of innovative therapies for Renal patients who have CKD stage 1 and 2
| Lobbyist | Covered position, as disclosed |
|---|---|
| HEIDE BAJNRAUH New | — |
| JOHN BARDI New | — |
| JOHN JONAS New | — |
| MOLLY RYAN New | — |
| KAREN THIEL New | — |
| RICHARD THOMPSON New | — |
Government Issues GOV
Education on Otsuka as a company Improving the U.S. mental health care delivery system Lack of innovative therapies for Renal patients who have CKD stage 1 and 2
| Lobbyist | Covered position, as disclosed |
|---|---|
| HEIDE BAJNRAUH New | — |
| JOHN BARDI New | — |
| JOHN JONAS New | — |
| MOLLY RYAN New | — |
| KAREN THIEL New | — |
| RICHARD THOMPSON New | — |
Medical/Disease Research/Clinical Labs MED
Education on Otsuka as a company Improving the U.S. mental health care delivery system Lack of innovative therapies for Renal patients who have CKD stage 1 and 2
| Lobbyist | Covered position, as disclosed |
|---|---|
| HEIDE BAJNRAUH New | — |
| JOHN BARDI New | — |
| JOHN JONAS New | — |
| MOLLY RYAN New | — |
| KAREN THIEL New | — |
| RICHARD THOMPSON New | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| OTSUKA PHAMACEUTICAL CO., INC. | Japan | Japan | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.